Is Labiaplasty Right for You? A Guide to Costs, Benefits, and Realistic Expectations
Why Choose Nazarian Plastic Surgery for Weight Loss With Tirzepatide?
Significant weight loss is a medical issue that deserves medical treatment. Board-certified plastic surgeon Dr. Sheila Nazarian is widely acclaimed for her transformative therapies and personalized treatment plans. Prospective patients can witness her compassionate and comprehensive approach to patient care on her Emmy-nominated Netflix series Skin Decision. When working with weight-loss patients, Dr. Nazarian develops a holistic treatment plan that combines lifestyle changes with carefully monitored medication support.
If you are obese or overweight and have tried to lose weight without success, you may be a candidate for weight loss with tirzepatide. Tirzepatide is a revolutionary medication that has shown remarkable results in helping obese and overweight patients achieve and maintain their goals when combined with diet and lifestyle changes. Achieve healthy body weight reduction, cultivate long-term wellness, and embrace confidence that ripples throughout every area of your life with our team’s personalized care.
Tirzepatide is a state-of-the-art medication originally developed for people with type 2 diabetes. It has also been FDA-approved to support weight reduction and chronic weight management. Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, meaning it mimics the actions of two naturally occurring incretin hormones that regulate blood sugar, appetite, and metabolic health. By activating the GIP and GLP-1 receptors, tirzepatide promotes feelings of fullness and satiety while slowing gastric emptying, which leads to reduced caloric intake. For patients with type 2 diabetes, tirzepatide has been shown to help regulate blood glucose levels.
Administered via once-weekly subcutaneous injection, tirzepatide works on multiple pathways in the brain and digestive system to provide significant weight loss results when used to support dietary changes and increased physical activity. The results of a large clinical trial published in 2023 demonstrated an average body weight decrease of 18.4 percent in patients taking tirzepatide.
For information about Semaglutide, click here.
At our practice in Los Angeles Tirzepatide is both simple and effective, requiring just a weekly, self-administered subcutaneous injection from the comfort of your home. Throughout your treatment, Dr. Nazarian will be by your side to answer your questions, monitor your progress, and ensure your smoothest experience and optimal results.
Tirzepatide promotes weight loss in patients who are overweight (with a BMI of 27 or higher), obese (with a BMI of 30 or higher), or have type 2 diabetes. Weight loss offers a number of health and cosmetic benefits to help you feel beautiful inside and out.
Enhanced Health Through Weight Loss:
Emotional and Cosmetic Benefits of Weight Loss Treatment:
Candidates for weight loss with tirzepatide include adults with obesity (a BMI of 30 or higher) or those who are overweight (a BMI of 27 or higher) with at least one weight-related medical condition, such as type 2 diabetes, hypertension, or dyslipidemia. Ideal candidates should be in generally good health and have realistic expectations about their results.
Tirzepatide is not recommended for individuals with a history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), severe hypersensitivity to the drug, severe gastrointestinal disease, or pancreatitis, as well as pregnant or breastfeeding women and those with severe kidney disease.
Dr. Nazarian will review your medical history, including any current medications, allergies, and chronic health conditions. This thorough assessment ensures that tirzepatide is a safe and effective weight loss option tailored to your specific health needs.
When considering treatment with tirzepatide Los Angeles patients who choose us appreciate that there is no downtime or recovery required. You will be free to administer your subcutaneous tirzepatide injections at home, in the office, or on vacation without missing a moment of the things you love. You can return to all of your regular activities immediately after your treatment.
You may begin to notice the effects of your tirzepatide treatment within just a few weeks. However, it will take about 16 weeks to see the full results of your weight reduction treatment. Tirzepatide is intended to be taken long-term for continued weight management. It is important to note that treatment discontinuation can result in appetite hormones reverting and weight regain.
Tirzepatide is safe and effective for the majority of weight loss patients. However, there are some conditions that may contraindicate treatment with tirzepatide, such as severe gastrointestinal disease, gastroparesis, and type 1 diabetes. If you have a personal or family history of chronic kidney disease, type 1 diabetes, diabetic neuropathy, multiple endocrine neoplasia syndrome type 2 (MEN 2), thyroid cancer, gastroparesis, or depression, Tirzepatide might not be a safe weight loss treatment regimen.
The key distinction is that tirzepatide is a dual GIP and GLP-1 receptor agonist, whereas Semaglutide only targets the GLP-1 receptor. This dual mechanism gives tirzepatide an enhanced ability to regulate appetite, calorie intake, and blood sugar. In clinical trials, tirzepatide demonstrated greater weight loss efficacy compared to Semaglutide.
As with any medication, side effects are possible with tirzepatide. The most common side effects of tirzepatide are related to the gastrointestinal tract and may include diarrhea, vomiting, constipation, decreased appetite, and bloating. Other possible side effects are changes in vision, injection site reactions, and mild allergic reactions.
Yes, subcutaneous tirzepatide is a prescription weight loss medication and must be prescribed by your doctor.
Clinical trials have determined that tirzepatide is associated with certain rare but serious adverse events in some patients, including developing pancreatitis, gallbladder problems, diabetic retinopathy, serious allergic reactions, or acute kidney injury. Lab animals have developed medullary thyroid carcinoma (a type of thyroid cancer) after being exposed to tirzepatide, but any link between tirzepatide and thyroid cancer in humans is unclear. Tirzepatide can also lead to low blood sugar if combined with certain medications.
